NCT00085254View on ClinicalTrials.gov

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma
Interventions
DRUG

cilengitide

Given IV

DRUG

temozolomide

Given orally

RADIATION

radiation therapy

Undergo radiotherapy

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (8)

19104

University of Pennsylvania, Philadelphia

21287

Johns Hopkins University, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

30322

Emory University, Atlanta

35294

University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic Foundation, Cleveland

48202

Henry Ford Hospital, Detroit

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00085254 - Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter